Insider trades
Merdad Parsey, Director of ArriVent BioPharma AVBP, has filed 0 purchases and 18 sales on the open market. The latest trade was on 06/18.
Merdad Parsey
Director
- Company
- ArriVent BioPharma AVBP
- First filing
- 23/01/03
- Trades
- 88 trades
- Buys / sales
- 0 / 18
- 12-month net buying
- No record
- Last trade
- 06/18
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
GILD | Open-market sale10b5-1 plan | 24/11/27 | 24/11/29 | 164,211 sh5 trades | $91.92avg. | $15,093,700.46 | −67.0% |
GILD | Open-market sale10b5-1 plan | 24/11/06 | 24/11/07 | 25,590 sh2 trades | $91.50avg. | $2,341,485 | −20.4% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 24/10/01 | 24/10/02 | 2,000 sh | $83.83 | $167,660 | −2.0% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 24/09/12 | 24/09/13 | 21,246 sh | $84.50 | $1,795,287 | −17.2% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 24/07/01 | 24/07/01 | 2,000 sh | $68.63 | $137,260 | −2.0% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 24/04/01 | 24/04/02 | 2,000 sh | $72.96 | $145,920 | −2.0% |
GILD | Open-market sale10b5-1 plan | 24/02/28–24/02/29 | 24/02/29 | 10,230 sh2 trades | $72.83avg. | $745,010.2 | −9.9% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 23/09/12 | 23/09/13 | 1,501 sh | $76.99 | $115,561.99 | −2.1% |
Gilead SciencesGILD | Open-market sale10b5-1 plan | 23/06/13 | 23/06/14 | 1,485 sh | $76.90 | $114,196.5 | −4.8% |
Gilead SciencesGILD | Open-market sale | 23/03/13 | 23/03/14 | 6,126 sh | $78.99 | $483,892.74 | −8.0% |
Gilead SciencesGILD | Open-market sale | 23/03/01 | 23/03/02 | 12,984 sh | $79.96 | $1,038,200.64 | −15.6% |
Gilead SciencesGILD | Open-market sale | 22/12/30 | 23/01/03 | 553 sh | $85.33 | $47,187.49 | −1.2% |
